Arcturus Therapeutics will release fourth quarter and fiscal year 2025 financial results after market close on March 3, 2026, followed by a conference call at 4:30 p.m. Eastern Time.
CSL Seqirus announced that neffy adrenaline nasal spray has been approved in Australia for emergency treatment of anaphylaxis in adults and children 15kg+ and aged four years and over, marking the first new adrenaline administration method approved in over 30 years.
The FDA mandated febrile seizure warnings for flu vaccines and rejected Moderna's mRNA flu vaccine application, with a political appointee overruling agency staff despite no safety concerns identified.
